MISSISSAUGA & RICHMOND HILL, ON–(Marketwired – Nov 4, 2015) – CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics (“IVD”) testing market, announced today that it, and its newly created Canadian subsidiary, have entered into a definitive asset purchase agreement to acquire substantially all of the assets of Plasticap. CardioGenics previously announced on October 5, 2015 that it had entered into a binding letter of intent to acquire substantially all of Plasticap’s assets.
The asset purchase agreement covers all assets of Plasticap as well as all current and future contracts. The acquisition of two related real property locations that are part of the overall acquisition will close in separate transactions, which are currently being finalized by the parties.
Full Article Here: www.marketwired.com
The post CardioGenics Enters Into Asset Purchase Agreement to Acquire All Assets of Richmond Hill Based Plasticap appeared first on Toronto Area's Tech Hub.